Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
1.
J Affect Disord ; 32(2): 105-14, 1994 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-7829762

RESUMO

In a 6-week double-blind study, 220 patients with major depression (mostly outpatients) were randomly assigned to receive a fixed dose of brofaromine 150 mg daily (n = 111) or placebo (n = 109) after a 1-week single-blind placebo washout. Except for the HAM-D sleep items, brofaromine was superior to placebo on measures of depression as determined by the four methods of assessing drug efficacy: (1) psychiatric symptom rating (HAM-D 17-item less the three sleep items); (2) self-rating scale (Beck Depression Inventory); (3) Clinical Global Assessment of Efficacy; and (4) drop-out rate due to lack of efficacy. Most commonly reported adverse events with brofaromine were: headache, nausea, dizziness and sleep disturbance. Brofaromine was found to be an effective antidepressant, superior to placebo with a good tolerability profile.


Assuntos
Transtorno Depressivo/tratamento farmacológico , Inibidores da Monoaminoxidase/administração & dosagem , Piperidinas/administração & dosagem , Adolescente , Adulto , Transtorno Depressivo/psicologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Inibidores da Monoaminoxidase/efeitos adversos , Inventário de Personalidade , Piperidinas/efeitos adversos
2.
Clin Neuropharmacol ; 16 Suppl 2: S77-82, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8313401

RESUMO

Monoamine oxidase (MAO) inhibitors are known to be effective in panic disorder, but a high incidence of adverse reactions have limited their use. The new, selective, and reversible MAO-A inhibitors exemplified by brofaromine and moclobemide do not require dietary restrictions, have fewer drug interactions, and are better tolerated. This paper reports a randomized, double-blind, 8-week trial in which the efficacy and safety of brofaromine was compared to clomipramine in patients with panic disorder with or without agoraphobia. Both treatments achieved a significant and comparable reduction in the number of panic attacks, and were equally effective in all the parameters measured. Side effects were typical of the drug class. Further trials are required to evaluate this promising new treatment.


Assuntos
Clomipramina/uso terapêutico , Inibidores da Monoaminoxidase/uso terapêutico , Monoaminoxidase/metabolismo , Transtorno de Pânico/tratamento farmacológico , Piperidinas/uso terapêutico , Agorafobia/tratamento farmacológico , Agorafobia/psicologia , Clomipramina/efeitos adversos , Método Duplo-Cego , Humanos , Inibidores da Monoaminoxidase/efeitos adversos , Transtorno de Pânico/psicologia , Piperidinas/efeitos adversos , Escalas de Graduação Psiquiátrica
3.
Clin Neuropharmacol ; 16 Suppl 2: S51-4, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8313397

RESUMO

Brofaromine is a new, reversible, and selective type-A monoamine oxidase inhibitor (MAOI) that also has serotonin reuptake inhibitory properties. Its dual pharmacologic effects offer promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with standard drugs. A multicenter, double-blind, placebo-controlled study including 220 patients was undertaken to evaluate the efficacy and safety of brofaromine in major depression. This study of a fixed-dose design and 6 weeks' duration found that brofaromine was significantly better than placebo on the Overall Evaluation of Efficacy, Beck self-rating scale, HAM-D Bech subscale, HAM-D total 14 items (minus the three sleep items), HAM-D depressed mood item and retardation factor, and worse than placebo on the insomnia items of HAM-D. Significantly more patients on placebo than on brofaromine did not complete the trial due to lack of efficacy. In comparative controlled studies (n = 899), brofaromine was found to be at least as efficacious as tricyclic antidepressants (imipramine) and standard MAOIs (tranylcypromine and phenelzine). Reductions of at least 50% in the HAM-D total score were seen in 58-66% of patients treated with either brofaromine or imipramine (n = 609). Brofaromine also was found to be of comparable efficacy to tranylcypromine in two clinical trials (n = 132), one of which included patients considered to have a treatment-resistant depression (n = 39). In another double-blind study that compared brofaromine (150 mg/day) to phenelzine (45 mg/day) (n = 158), there was no difference between brofaromine and phenelzine.


Assuntos
Antidepressivos/uso terapêutico , Transtorno Depressivo/tratamento farmacológico , Inibidores da Monoaminoxidase/uso terapêutico , Piperidinas/uso terapêutico , Adolescente , Adulto , Idoso , Canadá , Transtorno Depressivo/psicologia , Método Duplo-Cego , Feminino , Humanos , Imipramina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Fenelzina/uso terapêutico , Escalas de Graduação Psiquiátrica , Tranilcipromina/uso terapêutico
4.
Int Clin Psychopharmacol ; 14(2): 101-12, 1999 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10220125

RESUMO

The primary objective of this study was to evaluate the efficacy, safety and tolerability of remoxipride (controlled release) versus haloperidol in patients with negative symptoms. The study comprised a multicentre, randomised, double-blind, parallel-group clinical trial. Two hundred and five patients were randomised to either remoxipride or haloperidol. Patients eligible for this study were aged 18-65 years, met the DSM-III-R diagnosis for chronic schizophrenia and the Positive and Negative Symptoms Scale (PANSS) criteria for predominant negative symptoms. There was a statistically significant reduction in the PANSS scores of at least 20% from baseline to last rating for 39 remoxipride (49.4%) and 45 haloperidol (47.6%) treated patients. There were no statistical differences found between the two treatment groups with respect to improvement of negative symptoms and adverse events. The PANSS data suggest that both remoxipride and haloperidol improve the cluster of negative symptoms concerned with social functioning. In addition, the design of the study provides a methodology that is appropriate to the study of primary negative symptoms in schizophrenia.


Assuntos
Haloperidol/uso terapêutico , Remoxiprida/uso terapêutico , Esquizofrenia/tratamento farmacológico , Psicologia do Esquizofrênico , Adulto , Preparações de Ação Retardada/efeitos adversos , Preparações de Ação Retardada/uso terapêutico , Método Duplo-Cego , Feminino , Haloperidol/efeitos adversos , Humanos , Masculino , Escalas de Graduação Psiquiátrica , Remoxiprida/efeitos adversos
15.
Can Med Assoc J ; 102(9): 939-42, 1970 May 09.
Artigo em Inglês | MEDLINE | ID: mdl-4157149

RESUMO

A placebo-controlled, comparative clinical study was conducted to test the hypothesis that nicotinic acid as an adjuvant medication has a beneficial therapeutic effect over and above the effect which can be achieved by the administration of phenothiazine drugs alone, over a six-month period, in newly (recently) admitted schizophrenic patients.The most important single finding was that no statistically significant therapeutic difference was seen between the active treatment and the placebo groups; i.e., the addition of nicotinic acid or nicotinamide to the regular phenothiazine treatment regimen did not have any measurable therapeutic effect in this sample of patients. It was shown that patients in the placebo group received a lower total daily amount of phenothiazine drugs than those on either of the active substances. Furthermore, it was noted that the addition of the active substances did not reduce the number of days of hospitalization.


Assuntos
Ácidos Nicotínicos/uso terapêutico , Esquizofrenia/tratamento farmacológico , Adulto , Ensaios Clínicos como Assunto , Feminino , Humanos , Tempo de Internação , MMPI , Masculino , Pessoa de Meia-Idade , Ácidos Nicotínicos/administração & dosagem , Fenotiazinas/administração & dosagem , Fenotiazinas/uso terapêutico , Escalas de Graduação Psiquiátrica
16.
Brain Topogr ; 6(1): 21-5, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8260322

RESUMO

Automated artifact classification of quantified EEG (QEEG) epochs from 9 males using linear discriminant analysis showed greater than 85% agreement with judges' opinions. These results were replicated (n = 600 epochs for each sample). Testing the entire sample (n = 5800) illustrated reliable eye artifact (94%) but reduced muscle artifact classification (70%) accuracy. Agreement was lowest in the case of more subtle forms of muscle artifact (i.e., low amplitude muscle), however, less than 4% of these were wrongly classified as non-artifact. Improved data collection techniques retaining high frequency energies are anticipated to improve muscle artifact recognition. Results indicate that low levels of artifact contamination would result when only those epochs classified as non-artifact were accepted for inclusion in further analysis.


Assuntos
Eletroencefalografia/normas , Reconhecimento Automatizado de Padrão , Piscadela/fisiologia , Eletrodos , Movimentos Oculares/fisiologia , Humanos , Masculino , Músculos/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA